NCT07857759 Cervical Lymphatic Microsurgery in Alzheimer's Disease
| NCT ID | NCT07857759 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Daniel Maliszewski |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-09 |
| Primary Completion | 2029-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-09 with a primary completion date of 2029-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study will evaluate whether microsurgical modification of cervical lymphatic drainage may influence blood biomarkers and clinical outcomes in people with mild Alzheimer's disease. Thirty participants will be randomly assigned in a 1:1 ratio to either a surgical intervention group or a control group. Participants in the intervention group will undergo supermicrosurgical lymphaticovenous anastomosis (LVA) and/or lymph node-to-vein anastomosis (LNVA) in the neck to create an alternative pathway for lymphatic drainage. The procedure may be performed manually or with robotic microsurgical assistance. Participants in the control group will receive clinical observation without surgery during the first 12 months. The primary objective is to assess the change in plasma phosphorylated tau 217 (p-tau217) from baseline to 12 months. The study will also assess changes in cognitive and functional measures, including the Clinical Dementia Rating Sum of Boxes (CDR-SB), Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Montreal Cognitive Assessment (MoCA), and Mini-Mental State Examination (MMSE), as well as the feasibility and safety of the surgical procedure. Participants will be assessed at baseline and at 3, 6, and 12 months. After completion of the 12-month observation period, participants in the control group may be offered the surgical procedure if they wish to undergo it.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Clinical diagnosis of mild Alzheimer's disease according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. * Clinical Dementia Rating (CDR) score of 0.5 to 1.0. * Mini-Mental State Examination (MMSE) score of 20 to 26. * Confirmation of Alzheimer's disease pathology using plasma biomarkers, with elevated phosphorylated tau 217 (p-tau217). * Stable pharmacological treatment for Alzheimer's disease for at least 3 months before enrollment. * Ability to provide informed consent or consent provided by a legally authorized representative. Exclusion Criteria: * Moderate or severe Alzheimer's disease. * Other neurodegenerative disorders or significant psychiatric disorders. * Previous major neck surgery or radiotherapy to the neck that may affect lymphatic drainage. * Contraindications to general anesthesia. * Active infection or coagulation disorders.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07857759 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07857759 currently recruiting?
Yes, NCT07857759 is actively recruiting participants. Contact the research team at danielmal2@gmail.com for enrollment information.
Where is the NCT07857759 trial being conducted?
This trial is being conducted at Gdansk, Poland, Słupsk, Poland.
Who is sponsoring the NCT07857759 clinical trial?
NCT07857759 is sponsored by Daniel Maliszewski. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.